Grace Therapeutics, Inc.
Financial highlights
| Metric | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 | FY 03/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0 | $196,000 |
| Cost of revenue | — | — | — | $0 | $76,000 |
| Research and development | $9.5M | $4.7M | $10.0M | $5.6M | $4.2M |
| Operating income | -$16.7M | -$12.9M | -$52.2M | -$15.6M | -$16.4M |
| Pretax income | -$12.8M | -$14.7M | -$52.0M | -$10.5M | -$19.7M |
| Income tax expense | -$3.2M | -$1.8M | -$9.5M | -$648,000 | $0 |
| Net income | -$9.6M | -$12.9M | -$42.4M | -$9.8M | -$19.7M |
| Balance Sheet | |||||
| Cash and equivalents | $22.1M | $23.0M | $27.9M | $30.3M | $50.9M |
| Current assets | $22.7M | $24.0M | $29.3M | $45.3M | $62.4M |
| Total assets | $72.0M | $73.3M | $79.1M | $128.6M | $62.5M |
| Current liabilities | $1.9M | $1.7M | $3.4M | $3.3M | $1.6M |
| Total liabilities | $5.4M | $11.6M | $11.2M | $20.4M | $6.8M |
| Stockholders' equity | $66.6M | $61.7M | $68.0M | $108.3M | $55.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$14.9M | -$12.3M | -$15.9M | -$17.2M | -$14.3M |
| Depreciation and amortization | $7,000 | $11,000 | $124,000 | $0 | $143,000 |
| Stock-based compensation | $730,000 | $913,000 | $1.8M | $1.3M | $1.2M |
| Impairments | $0 | $0 | $28.7M | $0 | $1.6M |
Shares outstanding 15.5M
Annual filing data through FY ended March 31, 2025; float as of July 4, 2026.